Abstract 2159P
Background
The International Society for Geriatric Oncology (SIOG) recommends the use of geriatric assessments (GA) or clinical adverse event risk predictors when managing older cancer patients. However, traditional GA and risk predictors are rarely utilized in the real-world setting due to limitations in time and resources. The objective of this study was to assess the performance of machine learning algorithms in predicting the risk of post-chemotherapy grade 3-5 toxicity in older Asian patients.
Methods
This study is based on a dataset of patients from a prospective study at the National University Cancer Institute, Singapore (NCIS) that successfully validated the CARG model in older Asian patients. In this study, 200 patients aged 70 years or older of various Asian ethnicities, with a solid tumor diagnosis and undergoing chemotherapy were prospectively recruited over the period of June 1, 2017, to January 1, 2019. We trained four machine learning models – Support Vector Machine (SVM), Random Forest (RF), Extreme Gradient Boosting (Xgboost), and Light Gradient Boosting Machine (Light DBM) to predict the outcomes of grade 3-5 (CTCAE version 4.0) adverse events post-chemotherapy.
Results
The median patient age was 74 years (IQR, 71 to 78), and 110 (55.0%) were male. 137 (68.5%) patients experienced grade 3 to 5 chemotherapy toxicity. The best-performing model for predicting grade 3-5 chemotherapy toxicity in the test set was the Xgboost model which achieved an area under the ROC curve (AUC) of 0.87. By comparison, the CARG clinical model and oncologist prediction of grade 3-5 toxicity achieved an AUC of 0.61 and 0.74 respectively in the test set. The best performing Xgboost model included elements of the CARG model in addition to clinical features such as the Karnofsky Performance Scale, number of co-morbidities and medications, current treatment line, “Timed-Up and Go”.
Conclusions
The Xgboost Machine Learning model was able to predict the occurrence of grade 3-5 toxicity post-chemotherapy in elderly Asian patients with a better performance compared to the CARG clinical model and oncologists’ predictions. These results will be further evaluated in external, prospective patient cohorts to validate them for clinical use.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National University Cancer Institute, Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07